http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018201339-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 |
| filingDate | 2018-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8aa2656183eabebb9a57f5faf7958d90 |
| publicationDate | 2019-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2018201339-B2 |
| titleOfInvention | Ascorbate formulations and methods of use as contrast agents |
| abstract | Abstract A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L. 3549334vl |
| priorityDate | 2015-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.